Vertex Stock Today

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:4em;padding-top: 25px;;'>VP</div>
Vertex Pharmaceuticals is trading at 294.45 as of the 12th of July 2020; that is -0.32% down since the beginning of the trading day. The stock's open price was 295.4. Vertex Pharmaceuticals has a very small chance of experiencing financial distress in the next few years but had a somewhat ok performance during the last 30 days. Equity ratings for Vertex Pharmaceuticals Incorpor are calculated daily based on the scoring framework. The performance scores are derived for the period starting the 13th of April 2020 and ending today, the 12th of July 2020. Click here to learn more.
Analyze Filter   Report: 29th of July 2020

7 100 

Vertex Pharmaceuticals Profile

The upcoming quarterly report is expected on the 29th of July 2020. Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in the United States and is traded on BATS Exchange. It employs 3000 people. more on Vertex Pharmaceuticals
Legal NameVertex Pharmaceuticals Incorpor
ChairmanJoshua BogerView All
Average Analyst Recommendation
Current trade recommendation based on an ongoing consensus estimate among financial analysis covering Vertex Pharmaceuticals. The Vertex consensus assessment is calculated by taking the average estimates from all of the analysts covering Vertex Pharmaceuticals
Piotroski F Score
Academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Vertex Pharmaceuticals financial position. Scores of 8 and 9 are usually clasified strong value stocks whereas scores of 2 or below are considered weak value stocks.
 5 - HealthyDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares232.9 M256.7 M
Moderately Down
Slightly volatile
Weighted Average Shares Diluted235.7 M260.7 M
Moderately Down
Slightly volatile
Net Cash Flow from Operations1.7 B1.6 B
Significantly Up
Slightly volatile
Total AssetsB8.3 B
Significantly Up
Slightly volatile
Total Liabilities1.8 B2.2 B
Significantly Down
Slightly volatile
Current Assets5.2 B4.8 B
Significantly Up
Slightly volatile
Current Liabilities1.4 B1.3 B
Significantly Up
Slightly volatile
Total Debt816.4 M756.7 M
Significantly Up
Slightly volatile
Return on Average Assets17.4416.1601
Significantly Up
Slightly volatile
Gross Margin97.4786.8417
Moderately Up
Asset Turnover0.520.5716
Significantly Down
Slightly volatile
Macroaxis Advice
Macroaxis buy hold or sell recommendation provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Vertex Pharmaceuticals available fundamental, technical, and predictive indicators. Current horizon is 30 days (very short) - details
Cautious HoldFairly Valued
Financial Strength
Vertex Pharmaceuticals financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Vertex Pharmaceuticals success along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
  Operating Cash Flow
Vertex Pharmaceuticals Incorpor (VRTX) is traded on BATS Exchange in USA and employs 3,000 people. The company currently falls under 'Large-Cap' category with current market capitalization of 76.34 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Vertex Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Vertex Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Vertex Pharmaceuticals conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 259.28 M outstanding shares of which 4.21 M shares are at this time shorted by private and institutional investors with about 2.04 trading days to cover. VERTEX PHARMACEUT currently holds about 4.19 B in cash with 2.06 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.16.
Check Vertex Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Vertex Stock Price Odds Analysis

Odds Down 294.45HorizonTargetOdds Up 294.45
91.84%30 days
Based on a normal probability distribution, the odds of Vertex Pharmaceuticals to move above the current price in 30 days from now is about 8.06 (This Vertex Pharmaceuticals Incorpor probability density function shows the probability of Vertex Pharmaceuticals Stock to fall within a particular range of prices over 30 days) .

Vertex Stock Institutional Holders

InstituionSecurity TypeTotal SharesValue
Nelson Van Denburg Campbell Wealth Management Group LlcCommon Shares900261 K
Mr Capital Management IncCommon Shares100.029 K
View Vertex Pharmaceuticals Diagnostics

Vertex Pharmaceuticals Income Statement Over Time

Vertex Pharmaceuticals Incorpor Income Statement is one of the three primary financial statements used for reporting Vertex's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Vertex Pharmaceuticals revenue and expense. Vertex Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period. Vertex Pharmaceuticals Selling General and Administrative Expense is fairly stable at the moment as compared to the past year. Vertex Pharmaceuticals reported Selling General and Administrative Expense of 389.55 Million in 2019. Income Tax Expense is likely to grow to about 16.2 M in 2020, whereas Consolidated Income is likely to drop (104.3 M) in 2020. View More Fundamentals

Vertex Stock Against Markets

Did you try this?

Run Positions Ratings Now


Positions Ratings

Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

Vertex Pharmaceuticals Upcoming and Recent Events

Vertex Pharmaceuticals Company Earnings Announcements Dates

Upcoming Quarterly Report29th of July 2020
Next Earnings Report4th of November 2020
Next Fiscal Quarter End30th of June 2020
Next Fiscal Year End4th of February 2021
Last Quarter Report31st of March 2020
Last Earning Announcement30th of June 2019

Vertex Pharmaceuticals Corporate Directors

William Young Independent Director
Alan Garber Independent Director
Margaret McGlynn Independent Director
Also please take a look at World Market Map. Please also try Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page